3 No-Brainer Stocks to Buy for Under $100 Right Now
Key Takeaways
What's the biggest misconception. The idea that you need a lot of money to get started is certainly a contender. The reality is that it doesn't take much up-front cash....
Article Overview
Quick insights and key information
5 min read
Estimated completion
investment
Article classification
June 28, 2025
06:35 AM
The Motley Fool
Original publisher
What's the biggest misconception
The idea that you need a lot of money to get started is certainly a contender
The reality is that it doesn't take much up-front cash
Com contributors have identified no-brainer stocks to buy for under $100 right now
Here's why they picked two big pharma stocks -- AstraZeneca (AZN -0. 24%) and Pfizer (PFE -0. 17%) -- along with one bio stock, Exelixis (EXEL 1
Image source: Getty Images
It's still time to buy the dip on this stock sper Junior Bakiny (AstraZeneca): Last year, U. -based pharmaceutical giant AstraZeneca faced significant headwinds
Legal issues in China rocked the drugmaker as its CEO in the country, Leon Wang, was investigated and arrested
This issue cast a cloud over what would have otherwise been a strong year for AstraZeneca, since its financial results were generally strong
Despite decent gains this year, the stock is down 10% over the trailing-12-month period, significantly lagging behind the S&P 500 (^GSPC 0
Investors should pounce on this opportunity to buy the stock
Here are three reasons why
First, AstraZeneca continues to der solid financial results
In the first quarter, the company's revenue increased by 7% year over year to $13
AstraZeneca's earnings per came in at $2. 49, 21% higher than the year-ago period
Second, AstraZeneca has a deep pipeline that should allow it to overcome patent cliffs
The company recorded 13 apvals or label expansions through the end of the first quarter
Some of AstraZeneca's mising candidates include a pair of investigational weight management medicines: AZD5004 and AZD6234
The company has almost 200 grams in its pipeline
Third, AstraZeneca looks reasonably valued
The company's forward price-to-earnings ratio of 16. 3 is almost identical to the healthcare industry's average of 16
AstraZeneca's s are changing hands for $71 apiece, as of this writing
The stock looks a no-brainer at current levels, given its strong underlying
Exelixis is a bio stock that's just starting to take off David Jagielski (Exelixis): Oncology company Exelixis has been experiencing a lot of growth recently and possesses even more potential in the long run
S of this bio stock were trading around $40 to start the week, and have risen by more than 25% year to date
Despite its already solid gains, this can still be a no-brainer buy if you're an investor looking for a good growth stock to simply hang on to for the long haul
The company's top drug, Cabometyx, has been apved to treat multiple types of cancers and has been driving the lion's of the revenue growth for the
Through the first three months of 2025, the company's top line rose by 36% to $513. 3 million, with nearly all of that coming from Cabometyx
The results were so strong that Exelixis has boosted its revenue guidance for the year by $100 million
The drug is in late-stage trials as a possible treatment to help with state cancer and renal cell carcinoma, which can add to its growing list of indications
Another mising drug and potential growth catalyst to watch out for is zanzalintinib, as it is also involved in multiple late-stage trials, including colorectal cancer
Exelixis stock is currently trading at just 19 times trailing earnings
But with some strong growth spects and the company generating an impressive 28% fit margin over the trailing 12 months, this can be a no-brainer buy to hang on to
Even though it's been beating the market this year, it's still not too late to add Exelixis stock to your portfolio
More to than meets the eye Keith Speights (Pfizer): I'll readily admit that, at first glance, Pfizer doesn't look a no-brainer stock to buy
The big drugmaker's price has plunged roughly 60% from its COVID-19 pandemic peak in late 2021
Pfizer stock is down 14% over the last 12 months, with its price currently hovering around $24
The company faces a major patent cliff over the next few years as well
However, there's more to Pfizer than meets the eye
Its dividend ranks high on the list
Pfizer's forward dividend yield tops 7%
The company's management remains committed to maintaining and growing the dividend going forward, too
Valuation is another big plus for Pfizer
Its s trade at only 8. 3 times forward earnings
By comparison, the average forward price-to-earnings ratio for the S&P 500 healthcare sector is 16
Pfizer's growth spects could also be better than many investors think
The drugmaker has several newer ducts for which sales continue to soar
Its pipeline features 108 grams in clinical development, 33 of which either await regulatory apval or are in late-stage testing
An ultra-high dividend yield
A dirt cheap valuation
Perhaps surprisingly strong growth spects
I think that's enough to make Pfizer a no-brainer stock to buy right now
David Jagielski has no position in any of the stocks mentioned
Keith Speights has positions in Pfizer
Sper Junior Bakiny has positions in Exelixis
The Motley Fool has positions in and recommends Exelixis and Pfizer
The Motley Fool recommends AstraZeneca Plc
The Motley Fool has a disclosure policy.
Related Articles
More insights from FinancialBooklet